Shiina A, Hasegawa T, Iyo M. Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report. World J Clin Cases 2021; 9(11): 2469-2477 [PMID: 33889612 DOI: 10.12998/wjcc.v9.i11.2469]
Corresponding Author of This Article
Akihiro Shiina, MD, MSc, PhD, Associate Professor, Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Inohana 1-8-1, Chuoh-ku, Chiba 260-8670, Japan. shiina-akihiro@faculty.chiba-u.jp
Research Domain of This Article
Psychiatry
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Shiina A, Hasegawa T, Iyo M. Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report. World J Clin Cases 2021; 9(11): 2469-2477 [PMID: 33889612 DOI: 10.12998/wjcc.v9.i11.2469]
World J Clin Cases. Apr 16, 2021; 9(11): 2469-2477 Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2469
Possible effect of blonanserin on gambling disorder: A clinical study protocol and a case report
Masaomi Iyo, Tadashi Hasegawa, Akihiro Shiina
Akihiro Shiina, Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Chiba 260-8670, Japan
Tadashi Hasegawa, Department of Psychiatry, Chiba University Hospital, Chiba 260-8670, Japan
Masaomi Iyo, Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
Author contributions: Shiina A acquired the study grant and developed the study protocol; Hasegawa T contributed to participant recruitment; Shiina A and Hasegawa T evaluated participant status; Shiina A wrote the manuscript; Iyo M was the administrator of the project; All authors approved the manuscript.
Supported byThe Grant from Council for Addiction Behavior Studies.
Institutional review board statement: The study protocol was approved by the Institutional Review Board of Chiba University Hospital, which approved the implementation of this study as a clinical trial on January 7, 2016 (G27039, No. 65).
Clinical trial registration statement: We registered this study protocol with the UMIN Clinical Trial Registry on Jan 20, 2016 (R000023855, UMIN000020669).
Informed consent statement: The researcher obtained written informed consent from every participant prior to the beginning of the trial.
Conflict-of-interest statement: This study was supported by a grant from the Council for Addiction Behavior Studies, a non-profit organization in Japan. The last author received research funds and a lecture fee from Dainippon Sumitomo Pharma. We have no other conflicts of interest to declare.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: This study completely adhered to the CONSORT 2010 statement.
Corresponding author: Akihiro Shiina, MD, MSc, PhD, Associate Professor, Division of Medical Treatment and Rehabilitation, Chiba University Center for Forensic Mental Health, Inohana 1-8-1, Chuoh-ku, Chiba 260-8670, Japan. shiina-akihiro@faculty.chiba-u.jp
Received: December 14, 2020 Peer-review started: December 14, 2020 First decision: December 31, 2020 Revised: January 8, 2021 Accepted: February 1, 2021 Article in press: February 1, 2021 Published online: April 16, 2021 Processing time: 109 Days and 10.7 Hours
ARTICLE HIGHLIGHTS
Research background
Gambling disorder is one type of mental disorders that has a serious impact on patient's life, as well as their families. There have been some treatment strategies developed, but none of them are decisively effective.
Research motivation
There are many who suffer from gambling disorder. We have been engaged in their treatment in the clinical setting, but several patients fail to be respond to treatment due to several reasons. We strongly want to develop treatment options for non-responders.
Research objectives
The aim of the research was to examine the effectiveness and safety of blonanserin, a novel dopamine D3 antagonist, on gambling disorder.
Research methods
We developed a study protocol in which participants take blonanserin up to 12 mg/d for 8 wk. We evaluated its effect and safety with several rating scales.
Research results
One patient participated in this clinical trial. She had improved clinical symptoms of gambling disorder, but due to an adverse effect, quit taking blonanserin.
Research conclusions
This case suggests the potential effect of blonanserin to mitigate the symptoms of gambling disorder. On the other hand, extrapyramidal side effect should be cautiously addressed.
Research perspectives
We believe the study protocol presented is applicable to a randomized controlled trial with larger sample size.
